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Objective: The aim of this study was to determine the role of serum prolidase activity and the possible association
with oxidative stress parameters in non-diabetic metabolic syndrome.
Methods: 30 obese patients without metabolic syndrome (MetS), 34 non-diabetic obese patients with MetS, and 23
volunteer control subjects were enrolled in the study. Fasting plasma glucose (FPG), plasma glucose following 75 g
glucose administration, high-density lipoprotein- cholesterol (HDL-C), high-density lipoprotein- cholesterol (LDL-C),
total cholesterol, triglyceride (TG), total antioxidant status (TAS), total oxidative status (TOS), oxidative stress index
(OSI), and prolidase activities of all subjects were analyzed.
Results: Prolidase levels was significantly higher in MetS group compared to both obese and control groups
(p < 0.001 and p < 0.05 respectively). Prolidase was also higher in the obese group than in the control group
(p < 0.05). Prolidase was negatively correlated with TAS and HDL-C (r = −0,362, p < 0.001; r = −0.320, p < 0.01,
respectively) and positively correlated with BMI, weight, waist-c, SBP, DBP, TG, TC, LDL-C.
Conclusion: Prolidase activity may have a role in the pathogenesis of metabolic syndrome.
Keywords: Metabolic syndrome, Non-diabetic, Obesity, ProlidaseIntroduction
Metabolic syndrome (MetS) is defined as the existence of
obesity, insulin resistance, glucose intolerance, hyperten-
sion, and dyslipidemia [1]. Subjects with MetS may be
obese but all obese patients may not have MetS. Both
MetS and obesity have been shown to have impacts on
cardiovascular mortality and morbidity [2].
Endothelial disfunction causes alterations in the arterial
vasculature and leads to micro- and macrovascular compli-
cations. The remodelling of the endothelial basal membrane,
resulted with erosion and thrombosis, increases the oxida-
tive stress and alters matrix metalloproteinases (MMPs) ex-
pression [3].
Prolidase, a member of the MMP family, is a cytosolic
imidodipeptidase, which specifically splits imidodipep-
tides with C-terminal proline or hydroxyproline. The en-
zyme plays an important role in the recycling of proline
from imidodipeptides for resynthesis of collagen and
other proline containing proteins [4]. Prolidase enzyme* Correspondence: drhkorkmaz@yahoo.com.tr
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unless otherwise stated.activity has been shown in plasma, erythrocytes, leuko-
cytes, dermal fibroblasts and various organs such as kid-
ney, brain, heart, thymus, uterus, lung, spleen and
pancreas [5,6]. It is demonstrated that the activity of this
enzyme may have a role in various disorders such as
chronic liver disease, osteoporosis, osteoarthritis, urae-
mia, and hypertension [7-11]. To the best of our know-
ledge, there is no data concerning the serum prolidase
activity in metabolic syndrome. Therefore, the aim of
this study was to determine the role of serum prolidase
activity in non-diabetic metabolic syndrome.Method
Subjects
Patients who were admitted for the evaluation of obesity
were recruited from the Endocrinology and Internal
Medicine outpatient clinic. A standard 75g oral glucose
tolerance test (OGTT) was administered to all partici-
pants, and patients were randomized to three groups ac-
cording to their affected glucose metabolism. Groups
included 30 obese patients without MetS and glucose in-
tolerance (mean age 33.67 ± 7.9 years, 2M and 28F), 34his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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± 6.8 years, 3M and 31F), and 23 sex and age- matched
healthy control subjects (mean age32.39 ± 4.7 years, 3M
and 20F).
Although the MetS group was composed of non-
diabetics, all the patients had varying degrees of glucose
intolerance or were insulin resistant. The control group
had normal OGTT. MetS is defined according to the cri-
teria accepted in the Third Report of the National Choles-
terol Education Program (NCEP) [12]. Hypertension and
hyperlipidemia were diagnosed for the first time at the ini-
tiation of the study, so no participant was using an anti-
hypertensive or anti-lipidemic drug before obtaining the
blood samples. Subjects having diabetes, heart failure, cir-
rhosis, infection, renal failure, pregnancy or malignancy;
those on antioxidants such as antihypertensive medica-
tions, lipid-lowering medications, and vitamin E; and
smokers were excluded.
Age, weight, height, body mass index (BMI: body weight
(kg)/height (cm)2), and systolic (SBP) and diastolic blood
pressures (DBP) of all subjects were recorded. Fasting
plasma glucose (FPG), plasma glucose following 75g glu-
cose administration, high density lipoprotein- cholesterol
(HDL-C), Low density lipoprotein-cholesterol (LDL-C),
total cholesterol (TC), triglyceride (TG), total antioxidant
status (TAS), total oxidative status (TOS), oxidative stress
index (OSI), and prolidase activities of all subjects were
analyzed. The study was approved by the local ethics com-
mittee, and all participants gave signed informed consent.
Blood samples and preparation
Blood samples were drawn after overnight fasting, and
serum samples were stored at −80°C until biochemical de-
termination of TAS, TOS and prolidase activities.
Measurement of total antioxidant status
Serum TAS was determined using a novel automated
measurement method developed by Erel [12]. In the
method, hydroxyl radical, the most potent biological rad-
ical, is produced first. In the assay, reagent 1 containing
ferrous ion solution is mixed with reagent 2, which con-
tains hydrogen peroxide. The sequentially produced radi-
cals, such as brown colored dianisidinyl radical cation
produced by the hydroxyl radical, are also potent radicals.
The anti-oxidative effect of the study sample against the
potent-free radical reactions, which are initiated by the
produced hydroxyl radical, is measured. The assay has ex-
cellent precision values, lower than 3%, and the results are
expressed as mmol Trolox Equiv./l.
Measurement of total oxidant status
Serum TOS was determined using a novel automated meas-
urement method developed by Erel [13]. Oxidants present
in the study sample oxidize the ferrous ion-o-dianisidinecomplex to ferric ion. The oxidation is enhanced by glycerol
molecules, which are abundantly present in the reaction
medium. The ferric ion makes a colored complex with xyle-
nol orange in an acidic medium. The color intensity, which
can be measured spectrophotometrically, is related to the
total amount of oxidant molecules present in the sample.
The assay is calibrated with hydrogen peroxide, and the re-
sults are expressed as μmol H2O2 Equiv./l.
Oxidative stress index
Percent ratio of TOS to TAS level was accepted as OSI
(OSI (Arbitrary Unit) = TOS (μmol H2O2 Equiv./l)/TAS
(mmol Trolox Equiv./l)) [10].
Prolidase measurement
Prolidase activity was determined by a photometric
method based on the measurement of the proline levels
produced by prolidase [14].
Serum samples (100 μl) were mixed with 100 μl of
serum physiological. A total of 25 μl of the mixture was
preincubated with 75 ml of the preincubation solution (50
mmol/l Tris HCl buffer pH 7.0 containing 1 mmol/l gluta-
thione, 50 mmol/l MnCl2) at 37°C for 30 min. The reac-
tion mixture, which contained 144 mmol/l gly-pro, pH 7.8
(100 ml), was incubated with 100 ml of preincubated sam-
ple at 37°C for 5 min. To stop the incubation reaction, 1
ml glacial acetic acid was added. After adding 300 ml Tris
HCl buffer, pH 7.8, and 1 ml ninhydrin solution (3 g/dl
ninhydrin was melted in 0.5 mol/l orthophosphoric acid),
the mixture was incubated at 90°C for 20 min and cooled
with ice. Absorbance was then measured at a 515 nm
wavelength to determine proline value.
Intraassay and interassay coefficient of variations (CVs)
were lower than 10%. We measured the serum prolidase
activity by the method optimized by Gültepe [15], which
is a modification of Myara and Chinard's methods [16,17]
based on the spectrophotometric determination of proline
levels liberated from glycyl-L-proline by prolidase enzyme.
Plasma TG, total cholesterol, LDL-C, and HDL-C concen-
trations were measured by automated chemistry analyzer
(Aeroset, Abbott) using commercial kits (Abbott).
Statistical analysis
Continuous variables were expressed as mean ± S.D, and
non-parametric data were expressed as median and ranges.
Categorical data were compared by Chi-square tests. One-
way ANOVA was used for multiple comparisons among the
groups, and the LSD test was used if any statistical signifi-
cance was found. Normality of distribution was evaluated
with the Kolmogorov–Smirnov test. Pearson correlation test
was used to evaluate any relationships between parameters.
All statistical tests were two-sided. P <0.05 was regarded as
significant for all analysis. All analyses were conducted using
SPSS 11.5 (SPSS for Windows 11.5, Chicago, IL, USA).
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Mean ages of the three groups were similar. SBP, DBP and
TG levels were significantly higher in the MetS group com-
pared to both obese and control groups (all p < 0.001)
(Table 1). Both obese and MetS groups had significantly
higher BMI levels than the control group (all p < 0.001 and
p < 0.001 respectively). The obese group had higher SBP
and DBP than the control group (all p < 0.001). MetS group
had significantly lower HDL-C levels than the control
group (p < 0.001). HDL-C levels was also lower in the obese
group than in the control group, but the difference was not
significant. In the MetS group 10 patients had only im-
paired fasting glucose (IFG), 2 impaired glucose tolerance
(IGT), 9 had both IFG and IGTand 13 were only insülin re-
sistant. Prolidase levels were significantly higher in MetS
group compared to both obese and control groups (p <
0.001 and p < 0.05respectively) and also in the obese group
compared to the control group (p < 0.05). TAS was lower
in both MetS and obese groups than in the control group
(p < 0.001 and p < 0.05 respectively). There wasn’t any sig-
nificant difference according to BMI levels between MetS
and obese groups. OSI was significantly higher in both
obese and MetS groups than in the control group (p <
0.001 and p < 0.001 respectively). The clinical and biochem-
ical data are shown in Table 1.
In correlation analysis, prolidase was negatively correlated
with TAS and HDL-C (r =−0,362, p < 0.001; r = −0.320,
p < 0.01) and positively correlated with BMI, weight, waist-c,
SBP, DBP, TG, TC, LDL-C ( r = 0.330, p = 0.002; r = 0.298
p = 0.006; r = 0.4 p <0.001; r = 0.367, p = 0.001; r = 0.358,Table 1 Clinical and metabolic parameters of MetS, Obese an
MetS (n = 34, 31M and 3F)
Age (years) 35.18 ± 6.8
Body weight (kg) 97.27 ± 12.6b,f
BMI (kg/m2) 38.91 ± 5.5b
Waist-C (cm) 106.85 ± 10.3b,f
SBP (mmHg) 136.77 ± 12.0a,b
DBP (mmHg)* 90(70–110)a,b
TC (mg/dl) 194.39 ± 35.6e
HDL (mg/dl) 44.39 ± 13.3b
TG (mg/dl) 174.91 ± 72.9a,b
LDL (mg/dl) 113.68 ± 37.4
TOS (mmol H2O2 Equiv./l) 13.94 ± 2.19e,f
TAS (mmol Trolox Equiv./l) 0.95 ± 0.1a,b
OSI (arbitrary unit) 14.67 ± 2.2a,b
FPG (mg/dl) 102.88 ± 13.3b
Prolidase 708.93 ± 10.4b,f
BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; H
syndrome; OSI, oxidative stress index SBP, systolic blood pressure; TAS, total antioxi
Waist-C, waist circumference. *Data in which non-parametric tests were used and e
control; cobese versus control. P < 0.01: dMetS versus obese; eMetS versus control. Pp = 0.001; r = 0.293, p = 0.008; r = 0.297, p = 0.006; r = 0.306,
p = 0.005, respectively; Table 2). These associations were
confirmed in the multiple regression analysis ( R2 = 0,226,
p = 0,001). In multivariate logistic regression analysis proli-
dase activity was found to be an important predictor for
MetS (A one unit change in prolidase would make the MetS
1,115 as likely to ocur; R2 = 0,324, p = 0,001).
Discussion
In this study, we investigated the possible association be-
tween serum prolidase activity and non-diabetic meta-
bolic syndrome.We found a significant increase in serum
prolidase activity, a member of MMPs, in patients with
non-diabetic metabolic syndrome compared to obese or
healthy control groups. A significant correlation of
serum prolidase activity was also determined both with
increased BMI, weight, waist-c, SBP, DPB, TG, TC, LDL-
C and decreased TAS and HDL-C levels.
MetS is defined as the existance of obesity and at least
other two factors among hypertension, dyslipidemia and
diabetes mellitus or glycemia of >100 mg/dl [3]. Endothelial
dysfunction in MetS leads cardiovascular risk accompained
by high morbidity and mortality. Increased oxidative stress
and altered MMPs are shown two of the factors that play in
the pathogenesis of MetS. Prolidase, a member of MMPs,
plays an important role in collagen metabolism and extra-
cellular matrix remodeling [4,18]. Prolidase enzyme activity
has been investigated in various disorders such as chronic
liver disease [7], osteoporosis [8], osteoarthritis [9], uremia
[10], diabetic neuropathy [19], hypertension [11], coronaryd control groups
Obese (n = 30, 28M and 2F) Control (n = 23, 20M and 3F)
33.67 ± 7.9 32.39 ± 4.7
92.07 ± 19.2c 60.30 ± 10.3
36.59 ± 5.2c 22.93 ± 3.4
99.73 ± 13.2c 75.52 ± 8.1
118.67 ± 13.1c 105.65 ± 7.7
80(70–100)c 60(50–80)
181.66 ± 24.2 168.13 ± 24.7
42.14 ± 9.9 55.65 ± 5.2
100.07 ± 35.3 73.44 ± 30.6
117.76 ± 23.4h 97.80 ± 21.9
12.74 ± 2.1 13.05 ± 2.3
1.10 ± 0.1h 1.16 ± 0.1
11.48 ± 2.3 10.65 ± 2.4
97.94 ± 7.4h 90.87 ± 9.8
703.17 ± 8.1h 696.69 ± 11.5
DL, high-density lipoprotein; LDL, low-density lipoprotein; MetS, metabolic
dant status; TC, total cholesterol;TG, triglyceride; TOS, total oxidative status;
xpressed as median (range). P < 0.001: aMetS versus obese; bMetS versus
< 0.05: fMetS versus obese; gMetS versus control; hobese versus control.
Table 2 Correlations between prolidase, and other clinical and metabolic parameters
BMI WEIGHT WAIST-C SBP DBP TG TC HDL-C LDL-C TAS
PROLIDASE
R 0.330 0.298 0.400 0.367 0.358 0.293 0.297 −0,320 0,306 −0,362
P 0.002 0.006 <0.001 ,001 ,001 ,008 ,006 ,003 ,005 ,001
BMI
R 0.925 0.892 0.591 0.675 0.423 0.245 −0.304 0.170 −0.437
P <0.001 <0.001 <0.001 <0.001 <0.001 0.023 0.004 0.125 <0.001
WEIGHT
R 0.915 0.581 0.669 0.427 0.311 −0.302 0.234 −0.406
P <0.001 <0.001 <0.001 <0.001 0.004 0.005 0.034 <0.001
WAIST-C
R 0.594 0.675 0.481 0.322 −0.292 0.220 −0.434
P <0.001 <0.001 <0.001 0.002 0.006 0.046 <0.001
SBP
R 0.844 0.436 0.298 −0.197 0.161 −0.494
P <0.001 <0.001 0.005 0.069 0.147 <0.001
DBP
R 0.382 0.333 −0.217 0.218 −0.409
P <0.001 0.002 0.044 0.048 <0.001
TG
R 0.351 −0.166 −0.033 −0.379
P 0.001 0.133 0.767 <0.001
TK
R −0.006 0.849 −0.326







BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MetS, metabolic syndrome; SBP, systolic blood
pressure; TG, triglyceride; Waist-C, waist circumference; TAS, total antioxidant status.
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studies revealing the role of MMPs in MetS. Goncalves
et al. reported an increase in pro-MMP-9, MMP-8 and
TIMP-1 levels while without any difference in MMP-2,
MMP-3 and TIMP-2 levels compared to healthy controls
[22]. Additionally, an increase in MMP-8 levels in MetS pa-
tients [23] and elevated levels of MMP-2 activity, but not of
MMP-9 in non-diabetic MetS [24] was reported. On the
other hand, there are some studies in the literature regard-
ing MMPs profile in obesity [24-29], diabetes mellitus
[30-33] hypertension [34-36] and dyslipidemia [37,38], clin-
ical conditions representing diagnostic criteria for the defin-
ition of the metabolic syndrome.We have shown previously that MetS and obesity may
alter oxidative stress, which contributes to atherosclerosis-
related cardiovascular events [39]. In this study we also
found a significant increase (p < 0.001) of OSİ levels and a
significant decrease (p < 0.001) of TAS levels in metabolic
syndrome and non-diabetic Mets group compared to
obese and healthy control groups similar to our previous
study [39].
We eveluated firstly serum prolidase activity in non-
diabetic metabolic syndrome and demonstrated its eleva-
tion in this patient group. Additionally, the correlation
analysis showed that prolidase activity had a significant
positive correlation with BMI, weight, waist-c, SBP, DBP,
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TAS and HDL-C in our study. Correlation between serum
prolidase activity and markers of oxidative stress pare-
meters in this study suggests the association of collagen
turnover and oxidative stress in non-diabetic MetS.
Serum prolidase activity was significantly higher in MetS
group compared to the only obese group. This may be re-
sulted from that hypertension, hypertriglyceridemia, low
HDL-C levels, IGT, IFG and insülin resistance, are found
more frequently in MetS compared to obesity. Logistic re-
gression analysis demonstrated that prolidase activity was
an important predictor for MetS as for the last point of
this study.
Demirbağ et al. [11] has found a significant correlation
between prolidase activity and presence and duration of
hypertension supporting our data. Yıldız et al. [20] also
showed that serum prolidase activity was positively corre-
lated with presence of hypertension, SBP and inversely
correlated with HDL-C levels. Hilali et al. [18] reported
that elevated serum prolidase activity and oxidative stress
may be associated with increased cardiovascular risk in
polycystic ovary syndrome and/or menstrual irregularities
associated with this syndrome. Serum prolidase activity
was suggested as a marker of osteoporosis in type 2 dia-
betes mellitus [8].
Consequently we suggest that evaluating prolidase ac-
tivity in subjects with non-diabetic MetS may be import-
ant as an independent predictor of the disease. However,
further studies in larger patient groups are needed to ex-
plain the role of serum prolidase activity in the patho-
genesis of metabolic syndrome.
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